Double-blind, Randomized, Multicenter, Placebo-Controlled Study to Characterize the Efficacy, Safety, and Tolerability of 24 Weeks of Evolocumab for LDL-C Reduction in Pediatric Subjects 10 to 17 Years of Age With HeFH
Phase of Trial: Phase III
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Evolocumab (Primary)
- Indications Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Acronyms HAUSER-RCT
- Sponsors Amgen
- 31 Aug 2017 Planned End Date changed from 12 Mar 2018 to 21 Jun 2019.
- 31 Aug 2017 Planned primary completion date changed from 12 Mar 2018 to 21 Jun 2019.
- 10 Jun 2017 Biomarkers information updated